CrushSCI.com
99.8平均天数
103中位天数
42最短天数
152最长天数
1122025发文量

Paper Review Records

全部论文审稿周期

11 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期;保留 PDF/DOI/网页源链接

80 天

Inhibiting or harnessing fratricide in CAR-engineered cell therapy: challenges and opportunities

作者
Andrew N. Gorobchenko; Karina T. Umbetova; Abdigaffor Gadaev; Nargiza Mahkamova; Nasiba Sabirova; Aziz Kubaev展开收起
作者单位
1. Department of Infectious Diseases, Institute of Public Health named after F.F. Erisman I.M,. Sechenov First Moscow State Medical University of the Russian Federation (Sechenov University), Moscow, Russia; 2. Department of Internal Medicine in Family Medicine, Tashkent State Medical University, Tashkent, Uzbekistan; 3. Republican Specialized Scientific and Practical Medical Center of Cardiology, Tashkent, Uzbekistan; 4. Bukhara State Pedagogical Institute, Bukhara, Uzbekistan; 5. Department of Maxillofacial Surgery, Samarkand State Medical University, Samarkand, Uzbekistan展开收起
PDF源文件 DOI 网页
124 天

Pharmacokinetic comparison of cisplatin administration via HIPEC and intravenous infusion in a porcine model

作者
Christina Harlev; Elisabeth Krogsgaard Petersen; Mats Bue; Lone Kjeld Petersen; Johanne Gade Lilleøre; Anne Vibeke Schmedes; Bo Martin Bibby; Maiken Stilling展开收起
作者单位
1. Department of Clinical Medicine, Aarhus University, Aarhus, Denmark; 2. Aarhus Denmark Microdialysis Research (ADMIRE), Orthopaedic Research Laboratory, Aarhus University Hospital, Aarhus, Denmark; 3. Department of Orthopaedic Surgery, Aarhus University Hospital, Aarhus, Denmark; 4. Department of Gynecology and Obstetrics, Odense University Hospital, Odense, Denmark; 5. Department of Clinical Research, University of Southern Denmark, Odense, Denmark; 6. Department of Biochemistry and Immunology, Lillebaelt Hospital, University Hospital of Southern, Vejle, Denmark; 7. Department of Biostatistics, Aarhus University, Aarhus, Denmark展开收起
PDF源文件 DOI 网页
42 天

Benefit of plasma cystatin C for carboplatin individual dosing in a patient with spinal amyotrophy

作者
Matthieu Gracia; Sabrina Marsili; Julien Vintejoux; Laurence Gladieff; Etienne Chatelut; Fabienne Thomas展开收起
作者单位
1. Univ Toulouse, Oncopole Claudius Regaud, IUCT-Oncopole, Inserm, CRCT, Toulouse, France; 2. Univ Toulouse, Oncopole Claudius-Regaud, IUCT-Oncopole, Toulouse, France展开收起
PDF源文件 DOI 网页
103 天

Lack of effects of S -equol-containing supplement on the pharmacokinetics of oral hormone therapy drugs for breast cancer

作者
Takehiko Sambe; Chiyo K. Imamura; Noriko Hida; Taigi Yamazaki; Takuya Mizukami; Kakei Ryu; Koya Fukunaga; Taisei Mushiroda; Haruna Miyakawa; Shigeto Uchiyama; Naoki Uchida; Shinichi Kobayashi展开收起
作者单位
1. Division of Clinical Pharmacology, Department of Pharmacology, Showa Medical University School of Medicine, Tokyo, Japan; 2. Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo, Japan; 3. Advanced Cancer Translational Research Institute, Showa Medical University, Tokyo, Japan; 4. Division of Clinical Research and Development, Department of Clinical Pharmacy, Showa Medical University School of Pharmacy, Tokyo, Japan; 5. RIKEN Center for Integrative Medical Sciences, Yokohama, Japan; 6. Nutraceuticals Research Institute, Otsuka Pharmaceutical Co., Ltd., Saga, Japan展开收起
PDF源文件 DOI 网页
120 天

Presence of drug-drug interactions between esomeprazole and an ALK tyrosine kinase inhibitor (Dirozalkib)

作者
Lin Fang; Xin Jiang; Kexiu Song; Ping Shi; Li Wang; Lingmei Xu; Xianghui Duan; Fei Liu; Feifei Sun; Rongxin Ban; Yaping Ma; Chenjing Wang; Yu Cao展开收起
作者单位
1. Phase I Clinical Research Center, The Affiliated Hospital of Qingdao University, Qingdao, China; 2. Department of Endocrinology and Metabolism, The Affiliated Hospital of Qingdao University, Qingdao, China; 3. Clinical Medicine Department, XuanZhu Biopharm Co., Ltd, Shijiazhuang, China; 4. Clinical Pharmacology Department, XuanZhu Biopharm Co., Ltd, Shijiazhuang, China; 5. Biostatistics Department, XuanZhu Biopharm Co., Ltd, Shijiazhuang, China展开收起
PDF源文件 DOI 网页
48 天

Association of DPYD rs4294451, plasma uracil concentration, and sex with 5-fluorouracil exposure in patients with gastrointestinal cancer

作者
Gabriel A. Brooks; Dylan B. Ness; Kathryn C. Hourdequin; Gregory H. Ripple; Manik Amin; Sierra Lord-Halvorson; Wahab A. Khan; Sophie J. Deharvengt; Vincent Busque; Konstantin H. Dragnev; Wenyan Zhao; Tor D. Tosteson; Lionel D. Lewis展开收起
作者单位
1. Dartmouth Cancer Center, Lebanon, USA; 2. Geisel School of Medicine, Lebanon, USA; 3. Department of Medicine, Dartmouth Hitchcock Medical Center, Lebanon, USA; 4. University of Chicago Comprehensive Cancer Center, Chicago, USA展开收起
PDF源文件 DOI 网页

FAQ

CANCER CHEMOTHERAPY AND PHARMACOLOGY审稿要多久?

截至2026-11-19,CrushSCI 收录了 CANCER CHEMOTHERAPY AND PHARMACOLOGY 的 11 篇完整审稿记录。最快一篇从收稿到录用用了 42 天(Benefit of plasma cystatin C for carboplatin individual dosing in a patient with spinal amyotrophy,2025-09-22 收稿,2025-11-03 录用),最慢一篇用了 152 天;平均 99.8 天,中位数 103 天。

Expert Matching · Case Demo

把投稿要求,转成可验证的期刊方案

说清专业、时限和作者背景,CrushSCI 结合真实审稿样本,给出拟题方向、期刊初筛与周期判断。

我们会在半小时内回复。

CrushSCI 在线

客户询问

我是环境工程专业,需要一篇 SCI,希望 3 个月内见刊。没有基金,也没有大牛挂名,可以投哪些期刊?

CrushSCI回复

可以。先按 90 天时限做可行性筛选,同步查找无基金、无知名作者挂靠的典型论文案例,作为选刊依据。重点核对研究质量与期刊 scope。

拟题建议
《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》

样本口径2026 年最近 5 篇有效论文样本

平均审稿59.6 天

中位数65 天

Contact CrushSCI

联系 CrushSCI

留下手机号或微信号,我们将与你确认学术润色、结构优化或一对一辅导咨询需求。

我们会在半小时内回复。

当前选择:学术咨询服务

预留联系方式

也可以直接发送邮件至 leader@crushsci.com

手机号和微信号至少填写一项,仅用于本次咨询联系,不会公开。